CD274 and esophageal squamous cell carcinoma: In a very small phase Ib trial, dose-limiting toxicity (DLT) of the combination of durvalumab (anti-PDL1 ab) + tremelimumab (anti-CTLA-4) + first-line chemotherapy with 5-fluorouracil and cisplatin was assessed in ESCC [36].